Contact Us
Drug Search Results
More Filters [+]

PRG-2311

Alternative Names: PRG-2311, PRG 2311, PRG2311
Latest Update: 2024-07-11
Latest Update Note: Clinical Trial Update

Product Description

CD19/BCMA-targeting CAR-T Cells for Refractory Lupus Nephritis and IgG4-Related Disease. (Sourced from: https://clinicaltrials.gov/study/NCT06497361)

Mechanisms of Action: CAR-T,CD19,BCMA

Novel Mechanism: No

Modality: Cell Therapy

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pregene Biotech
Company Location:
Company CEO:
Additonal Commercial Interests: Tongji Hospital

Clinical Description

Map of Global Clinical Trials for PRG-2311

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: IgG4-related Disease|Lupus Nephritis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
S114

P1

Recruiting

IgG4-related Disease|Lupus Nephritis

2027-07-01

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions